Share ownership United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/02/2026 GMT			5-day change	1st Jan Change
476.13 ^USD	+0.06%		-0.58%	-2.28%

01-26	United Therapeutics Corporation Announces Positive Results from Phase 1 Study of MiroliverELAP® in Patients with Acute Liver Failure	CI
01-26	United Therapeutics Says Its Experimental Liver Assist Device Met Primary Goal in Phase 1 Study	MT

Share class: United Therapeutics Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	74,811,109	43,820,714 ( 58.58 %)	30,166,590 ( 40.32 %)	58.58 %

Major shareholders: United Therapeutics Corporation

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.97 %	4,722,094	10.97 %	2 217 M $
Vanguard Fiduciary Trust Co. 9.699 %	4,176,016	9.699 %	1 961 M $
Wellington Management Co. LLP 5.67 %	2,441,492	5.67 %	1 146 M $
Renaissance Technologies LLC 5.048 %	2,173,392	5.048 %	1 020 M $
Avoro Capital Advisor LLC 4.697 %	2,022,222	4.697 %	949 M $
STATE STREET CORPORATION 4.465 %	1,922,609	4.465 %	903 M $
Wellington Trust Co., NA 3.249 %	1,398,781	3.249 %	657 M $
Geode Capital Management LLC 2.771 %	1,193,064	2.771 %	560 M $
AQR Capital Management LLC 2.291 %	986,478	2.291 %	463 M $
Darwin Global Management Ltd. 1.739 %	748,550	1.739 %	351 M $
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	89.01%
Other	8.29%
State Street Corp.	4.47%
Individuals	1.78%
Swedbank AB	0.75%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.21%
Governments	0.17%
Manulife Financial Corp.	0.14%
SEI Investments Co.	0.11%
First Financial Bankshares, Inc.	0.05%
Danske Bank A/S	0.05%
Skandinaviska Enskilda Banken AB	0.04%
Hancock Whitney Corp.	0.02%
MidWestOne Financial Group, Inc.	0.02%
Rathbones Group Plc	0.01%
The Allstate Corp.	0.01%
Ledyard Financial Group, Inc.	0.01%
Baader Bank AG	0.01%
The Bank of Nova Scotia	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	85.39%
United Kingdom	7.15%
Individuals	1.78%
Norway	1.69%
Australia	1.47%
Sweden	1.46%
Switzerland	1.22%
Canada	1.04%
France	0.78%
Japan	0.61%
Luxembourg	0.56%
Hong Kong	0.37%
Netherlands	0.35%
Germany	0.31%
Ireland	0.31%
New Zealand	0.23%
South Korea	0.15%
Denmark	0.13%
Austria	0.11%
Italy	0.07%
Belgium	0.06%
United Arab Emirates	0.03%
Singapore	0.03%
China	0.03%
Cayman Islands	0.02%
Taiwan	0.02%
Puerto Rico	0.02%
Finland	0.02%
Slovenia	0.02%
Spain	0.01%
South Africa	0.01%

Based on 1000 largest holdings

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâ€™s Afrezza (insulin human) Inhalation Powder.

Employees

1,305

Sector

Pharmaceuticals

Calendar

02-25 - Q4 2025 Earnings Release

More about the company